title: Epstein-Barr virus-related lymphoproliferative disorder, cytomegalovirus reactivation, and varicella zoster virus encephalitis during treatment of medulloblastoma.
abstract: The case of a 14-year-old girl who developed Epstein-Barr virus-related lymphoproliferative disorder, cytomegalovirus reactivation, and Varicella zoster virus encephalitis during treatment for medulloblastoma is described. The patient was diagnosed with a cerebral medulloblastoma and treated with systemic chemotherapy, intrathecal chemotherapy, and radiotherapy. Six months later, she developed persistent low-grade fever, abdominal pain, and vomiting. Several mucosal or ulcerated lesions of the stomach and colon were found on fiberscopy. The infiltrating cells were positive for CD20 and EBER1, and the diagnosis of lymphoproliferative disorder was made. CMV antigen was found in the peripheral lymphocytes at that time. At the same time, it was noted that the patient's language was inappropriate for her age, and a facial and abdominal rash, as well as a right facial palsy, had developed. She was then diagnosed as having VZV encephalitis, because VZV was detected in the CSF. She was treated subsequently with acyclovir and oral steroid, and the VZV encephalitis resolved. The lymphoproliferative disorder improved gradually with rituximab, ganciclovir, and total nutritional support. At the time of the development of the lymphoproliferative disorder and VZV encephalitis, the patient had severe lymphopenia and this may have caused these rare phenomena in a non-transplant setting.
authors: Department of Pediatrics, Shiga University of Medical Science, Shiga, Japan.
authors: Motoki
authors: M
authors: Ohta
authors: Takashi
authors: T
authors: Taga
authors: Akitaka
authors: A
authors: Nomura
authors: Hirofumi
authors: H
authors: Kato
authors: Tomoyuki
authors: T
authors: Takano
authors: Yoshihiro
authors: Y
authors: Maruo
authors: Yoshihiro
authors: Y
authors: Takeuchi
authors: Mitsuaki
authors: M
authors: Ishida
authors: Shigeru
authors: S
authors: Ohta
mesh_terms: D000212:Acyclovir / Q000008:administration & dosage / Q000627:therapeutic use; D000293:Adolescent; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage / Q000627:therapeutic use; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000628:therapy*; D003131:Combined Modality Therapy; D003586:Cytomegalovirus Infections / Q000188:drug therapy / Q000209:etiology*; D020804:Encephalitis, Varicella Zoster / Q000188:drug therapy / Q000209:etiology*; D020031:Epstein-Barr Virus Infections / Q000188:drug therapy / Q000209:etiology*; D005260:Female; D015774:Ganciclovir / Q000008:administration & dosage / Q000627:therapeutic use; D004854:Herpesvirus 4, Human; D006801:Humans; D016867:Immunocompromised Host; D007165:Immunosuppression Therapy; D008231:Lymphopenia; D008232:Lymphoproliferative Disorders / Q000175:diagnosis / Q000209:etiology*; D008527:Medulloblastoma / Q000628:therapy*; D000069283:Rituximab; D014775:Virus Activation
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000998:Antiviral Agents; D000069283:Rituximab; D015774:Ganciclovir; D000212:Acyclovir